USE OF SULFONYLBENZAMIDE COMPOUNDS IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS, LUPUS NEPHRITIS, OR SJOGREN'S SYNDROME

摘要

This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl 2 anti apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl- xL.